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ABSTRACT 
Background: Different techniques have classically been used to evaluate and assure the quality of 
medicines circulated on the market; one of the commonly uses is chemical analysis. However, some 
evidence has shown that there are other important indicators (e.g. bioequivalence, relative potency, 
etc.) that should also be considered when evaluating the quality of pharmaceutical products.     
Materials and Methods: A microbiological assay was conducted to compare the relative potency 
of two Ceftriaxone products (with a third one used as standard product) from the market using 3 
reference bacteria including Streptococcus pneumoniae, Klebsiella pneumoniae and Staphylococcus 
aureus. Serial dilutions were made with the corresponding 1, 4, 8, 16 and 32-fold Minimum 
Inhibitory Concentration (MIC) of Ceftriaxone against the bacteria under investigation. 
Results: The relative potency of one product compared to the standard product was estimated to be 
within the acceptable range of bioequivalence (89.6%), while the other product showed 
unacceptable relative potency (72.3%).   
Conclusions: The microbiological assay is an effective and simple method for comparing the 
equivalency of injectable products. A complaint reporting system about quality and effectiveness 
problems needs to be considered as a priority source of such information to inform decision-makers. 
Keywords: Microbiological assay, Ceftriaxone, quality assurance, relative potency and generic 
medicines. 
ifferent techniques have classically 
been used to evaluate and assure the 
quality of medicines circulated on the 
market. One of the most important techniques 
is chemical analysis, in which different 
methods of analysis can be used to assure 
quality. However, measurements of chemical 
content alone do not provide sufficient 
indication about the quality of drugs. 
Evidence has shown that there are other 
important indicators (e.g. bioequivalence, 
relative potency, etc.) that should also be 
considered when evaluating the quality of 
pharmaceutical products1.  
In 2009, a comprehensive study was 
conducted to evaluate the quality of 
medicines distributed on the private market in 
Khartoum, Sudan. The main method used for 
this assessment was chemical analysis. 
Approximately 10% of the samples tested in  
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this study failed to comply with reference  
standards specifications in terms of chemical 
analysis of Active Pharmaceutical Ingredients 
content. The results obtained in this 
unpublished quality survey from chemical 
tests were not sufficient, alone, to answer the 
complaints continuously reported from health 
professionals (doctors and pharmacists) 
regarding the quality issues related to these 
products. One of the products within this 
category which was often reported was 
Ceftriaxone powder for injection. Ceftriaxone 
is one of the third generation cephalosporins. 
It is administered intravenously or 
intramuscularly and has a broad spectrum of 
activity against Gram-positive and Gram-
negative aerobic, and some anaerobic, 
bacteria. From the results, we noted that 
Ceftriaxone was the most frequently reported 
generic that doctors took decisions about 
related to alterations in their patients’ 
treatment. These decisions were varied; there 
was either a shift to similar products (from 
different sources) or a shift to different 
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generics. We also noted that among the 
circulated Ceftriaxone (powder for injection) 
products on the market, there was one specific 
product reported in the majority of complaints 
received during the survey. The majority of 
the cases were referring to products imported 
from low income countries. 
Based on one study conducted previously in 
this area by Zuluaga and colleagues, it was 
recommended to benefit from the potential 
use and application of microbiological assays 
to determine the pharmaceutical equivalence 
of generic intravenous antibiotics2. The 
approach was found effective by other similar 
series of studies conducted by a team of 
researchers from the Wayne State University 
of Michigan - USA, to assess the usefulness 
of relative potency of pharmaceutical 
products3. This approach was adopted to 
investigate these complaints about the quality 
and effectiveness of Ceftriaxone further. 
Based on that, the main aim of this study was 
to verify the hypothesis that the difference in 
potency (equivalence) of Ceftriaxone 
products is a contributing factor to this 
problem in Sudan. To the best of our 
knowledge this was the first time to adopt this 
approach in Sudan, in large scale, for the 
purpose of monitoring the quality of 
pharmaceutical products. 
MATERIALS AND METHODS: 
Preparation of culture media: 
The media used for antibacterial screening 
tests were nutrient agar and nutrient broth. 
Twenty six grams of nutrient agar (from 
Scharlau Chemie, Spain) was suspended in 
one litre of distilled water and heated in 
boiling water bath to dissolve the media 
completely; this solution was then divided 
into 20 ml portions in small vials. Thirteen 
grams of nutrient broth (from Fine-Chem. 
LTD. India) was dissolved in one litre of 
distilled water, heated in a water bath to 
dissolve the media and divided into 10 ml 
portions in small vials. The prepared nutrient 
agar and nutrient broth media were sterilised 
by  autoclaving at 121 degrees (at 
atmospheric   of    15  pounds)  for 15 
minutes. 
Preparation of standard bacterial suspensions: 
Each 10 ml portion of sterilised nutrient broth 
was inoculated with a loopful of each 
bacterial slant agar culture and incubated for 
18-24 hours at room temperature. A 10% 
dilution of each liquid culture was prepared in 
sterilised normal saline and kept in a 
refrigerator. 
Preparation of serial dilutions of Ceftriaxone: 
Serial dilutions with corresponding 1, 4, 8, 16 
and 32-fold Minimum Inhibitory 
Concentration (MIC) of Ceftriaxone against 
the bacteria under testing were prepared. In 
table 1 the MIC90 for different bacteria is 
shown which was used to prepare the serial 
dilutions3. 
Table (1): Minimum Inhibitory Concentration 




Streptococcus pneumoniae 0.060 
Klebsiella pneumonia 0.125 
Staphylococcus aureus 4.000 
The equivalent amount of powder from 
different products was dissolved in distilled 
water to obtain the required dilutions. 
Antibacterial assay: 
The cup-plate agar diffusion method adopted 
in this study was that of Murray and others 
with some minor modifications, which was 
used to assess the antibacterial activity of the 
products4. From each of the standard stock 
suspensions, 0.1 ml was thoroughly mixed 
with 20 ml of sterile testing media in Petri 
dishes and left to solidify on a plain surface. 
Then, four cup-shape wells (10 mm 
diameter/each) were made in each plate using 
a sterile cork-borer (no.7). The agar discs 
were removed and alternate cups were filled 
with 0.08 ml sample of each concentration 
from the solution of one product at a time. 
The fourth alternate cup was filled with the 
solvent used (water) for control purposes 
using a sterile adjusted pipette. The plates 
were then incubated in the upright position for 
18-24 hours at room temperature. Three 
replicates were used for each solution against 
each tested organism. After the incubation 
periods indicated, the inhibition zone 
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diameters were measured and the mean value 
was tabulated. 
The products: 
Three products of Ceftriaxone sodium (1 gm 
powder for injection) were included in this 
study. One of these was the originator’s 
product, “Rocephin G03C10T02”, which is 
manufactured by Roche – Switzerland; for the 
purposes of this study, it was selected as the 
reference product. The other two products 
were chosen based on random selection 
process. The details of the products are shown 
in the table (2). 
Statistical analysis: 
The range of concentrations of each product 
was statistically satisfactory to produce a 
wide range of points sufficient for producing 
clear statistical data. The concentrations 
prepared and used in this assay include 0.125, 
0.5, 1.0, 4.0, 16.0 and 32.0 mg/ml (according 
to the MIC of the targeted bacteria). The 
assay was repeated using three concentrations 
of each antibiotic in triplicate for each 
microorganism. For the purpose of this 
analysis, the linearity and precision of the 
method used were all determined. This was 
achieved by plotting the log-transformed 
concentrations of each product against the 
inhibition zone in mm. The data followed a 
linear statistical model which was confirmed 
by the values of the intercept and slope of the 
best straight line when applied in the equation 
(y = b + mx, where b is the y-intercept and m 
is the slope). 
Table (2): Details of Products under testing 
Trade Company Country of origin Origin classification 
G03C10T01 C20 Switzerland High income level 
G03C10T02 C10 India Low income level 
G03C14T03 C14 Jordan Lower-middle-income level 
 
The x-intercept (log10 mg/L) and slope of the 
regression line with 95% confidence intervals 
(95% CI) were both calculated and used for 
regression analysis to determine the statistical 
significance of these variables2.  
The equivalencies of products from this 
experiment were concluded by comparing the 
slope and intersect of each product using a 
symmetrical parallel-line assay. In this 
analysis, and in accordance with the purpose 
of the study, potency was defined as the slope 
of the linear regression and concentration. In 
this case, and if we assume that the test 
products and the innovator are equivalent, 
then the products must show a trend of a 
parallel and overlaid curve with the curve of 
the innovator. At the same time, when there 
are parallel curves with different intercepts, 
this may indicate the existence of the same 
active ingredient but at different 
concentrations above or below that of the 
innovator product. The relative potency for 
each product to the potency of the innovator 
was calculated using the distance between the 
innovator line and that of the test product. The 
response values (diameter of inhibition zones) 
were calculated using the standard deviation 
and slope method and these were stated in 
term of means +/- the standard deviations and 
with the calculated coefficients of variation. 
To test the accuracy of the test, i.e. its ability 
to detect significant differences in the 
concentration, a standard curve was obtained 
using different concentrations of Ceftriaxone 
working standard solution with a potency of 
98.6%/L. This curve was compared with the 
curve of all products being investigated. 
RESULTS: 
Table (3) shows the potency estimates and 
other parameters derived from linear 
regression with their statistical comparison of 
the test product versus innovator using Curve 
Fitting Analysis. Figures (1) and (2) shows 
the log concentration-response relationship 
and the best straight line obtained from data 
from the microbiological assay of the 
innovator. In the case of Klebsiella 
pneumoniae and Staphylococcus aureus, the 
figure showed a linear relationship between 
the logarithm of the concentration (log10 
mg/L) and the diameter (mm) of inhibition 
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zones with relatively high coefficients of 
determination (r2 ranging from 0.97 to 0.78) 
and a statistically significant intercept and 
slope (P < 0.001 by ANOVA). On the other 
hand, the results for Streptococcus 
pneumoniae showed different trends. The 
main observation from the raw data showed 
that the response of the organism (growth 
inhibition) only appeared at higher 
concentrations. This result appeared at a 
concentration 32 times higher than the MIC90 
for this organism, i.e. 2mg/ml, and this was 
also observed for all products under 
investigation. This finding was significant on 
its own due to the fact that growth inhibition 
was expected to be at relatively lower 
concentrations. These outputs were not 
reported in any available studies about the 
microbiological response of Ceftriaxone 
against Streptococcus pneumoniae. 
Table 3: Summary of relative potencies and other parameters of Ceftriaxone products 
Product r2 Intercept ± SD P-value Slope ± SD P-value 
Potency 
estimate (%) 
Organism: Staphylococcus aureus 
G03C20T01 0.97 2.401 ± 0.205 0.000 0.027 0.000 100.0% 
G03C10T02 0.91 2.223 ± 0.187 0.000 0.026 0.000 84.3% 
G03C14T03 0.78 2.172 ± 0.164 0.000 0.027 0.000 70.% 
Organism: Klebsiella pneumoniae  
G03C20T01 0.97 2.198 ± 0.172 0.000 0.023 0.000 100.0% 
G03C10T02 0.91 2.023 ± 0.124 0.000 0.025 0.000 89.4% 
G03C14T03 0.78 2.089 ± 0.166 0.000 0.023 0.000 74.1% 
Organism: Streptococcus pneumonia 
G03C20T01 0.41 2.351 ± 0.311 0.000 0.022 0.000 100.0% 
G03C10T02 0.52 2.325 ± 0.324 0.000 0.024 0.000 51.4% 




Figure (1): Single dose-response curves for Ceftriaxone products against targeted organisms. 
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Figure (2): Combined dose-response curves for Ceftriaxone products against targeted organisms 
Excluding the data of Streptococcus 
pneumoniae and considering the data from 
other organisms, all of the products exhibited 
a different intercept (P < 0.005); the log 
concentration-response relationship for one of 
the generics (G03C20T02) was parallel and 
overlaid to the innovator linear curve without 
any significant difference (P < 0.005), while 
the curve of the other generic (G03C20T03) 
was parallel but not overlaid with the 
innovator linear curve. These findings 
indicate that generic G03C20T02 and generic 
G03C20T03 had the same biological activity 
(potency). On the other hand, generic 
G03C20T02 and generic G03C20T03 showed 
relative estimated potencies of 86.9% and 
72.3% of the originator product, respectively. 
All of these data indicate that generic 
G03C20T02 is pharmaceutically equivalent to 
the originator product while generic 
G03C20T03 did not show the same 
association. 
DISCUSSION: 
The results obtained from the chemical 
analysis tests used in the quality monitoring 
survey mentioned previously were not 
sufficient to answer the complaints from 
health professionals regarding the quality 
issues around Ceftriaxone powder for 
injection (especially for certain products). 
However, these products complied with 
reference standard specifications in terms of 
chemical content limits. This raised many 
questions regarding the reasons leading to 
these complaints about that specific product. 
No single reason prior to this study could be 
considered evidence for the primary cause of 
this observation.  
The equivalency of pharmaceutical products 
is an essential and basic criterion for proving 
the quality of any product1. In general, there 
are different methods that can be used by the 
regulatory authorities to evaluate these 
characteristic; including the in vitro /in vivo 
bioavailability studies and other methods like 
bioassays. The use of the bioassay method is 
not new in different pharmaceutical sciences; 
however, it has been used limitedly, and 
mainly, for pharmacokinetic studies5. Late in 
the 1980s, the bioassay method drew attention 
as a possible tool for establishing scientific 
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judgment about the pharmaceutical 
equivalence of certain categories of products 
like anti-infectives and vitamins6. This 
method could help to obtain more conclusions 
about the similarity and the differences 
between products that are supposed to contain 
similar and equivalent active ingredients. This 
is especially true when we consider the fact 
that any pharmaceutical formulation usually 
contains the active ingredient in addition to 
other substances (e.g. preservatives, 
impurities, etc.). In most of the cases, these 
materials were not considered during 
assessment of the quality or equivalency of 
generic products7. The statistical method 
adopted here was used for a similar study 
performed using other anti-infective 
intravenous preparations2. It was previously 
believed that the agar-diffusion assay is less 
reliable than other chemical methods (e.g. 
HPLC) because it suffers from a wide variety 
of biological errors. Still, this method is 
statistically suitable for use in such kinds of 
studies (equivalence and potency evaluation 
studies). The logic behind the statistics used 
in this study (and similar studies in general) 
was based on the assumption that: if two 
Ceftriaxone products were equivalent to each 
other, by obtaining two symmetrical and 
straight parallel lines (plotting of the mean 
zone size against the logarithmic 
concentration), then the relative potency of 
the test product to the reference product could 
be derived by calculating the distance 
between the two lines2. At the same time, 
these curves derived from the bioassay should 
not differ significantly from each other. 
The results obtained in this study support the 
reservations about Ceftriaxone products 
reported in quality monitoring surveys. The 
product G03C20T03 was not found to be 
equivalent to the reference product under 
testing. Accordingly, it is not anticipated to 
show a similar therapeutic profile and 
effectiveness. Considering the critical 
importance of anti-infectives (especially 
Ceftriaxone) to public health in Sudan and 
other similar countries, it has now become 
essential to investigate the assumption about 
the differences in therapeutic equivalency 
between the products available on the market. 
The equivalence and potency of 
intravenous/parenteral generic products of 
Ceftriaxone, away from clinical studies, 
cannot be evaluated using conventional 
physical and chemical methods alone. After 
carrying out this study, it was proven that 
using a well-designed microbiological 
bioassay should help medicines regularity 
authorities to perform such re-evaluations to 
check the quality of different products. In 
general, this study also highlighted the 
importance of expanding Post-Marketing 
Surveillance systems to check the quality and 
efficacy beyond the physiochemical analysis 
to include more tests including 
microbiological assays, bioassays, 
bioequivalence studies, minilabs, dissolution 
test, etc. as routine tests. 
CONCLUSION: 
In conclusion, this simple method of analysis 
is very important for any regulatory authority 
to be considered a routine process. The 
method provides a good tool for the accurate 
determination of the pharmaceutical 
equivalence of drugs in injectable dosages. 
This in fact is one of the considerable 
innovations for any quality monitoring system 
in the country related to injectable products. 
In addition, a complaint reporting system 
about quality and effectiveness problems 
needs to be considered as a priority source of 
such information to inform the decision 
makers. 
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